LBH589 and Gemcitabine in the Treatment of Solid Tumors - Contacts and Locations

LBH589 and Gemcitabine in the Treatment of Solid Tumors

This study is currently recruiting participants.

Study NCT00550199. Last updated on June 6, 2008. Information provided by Sarah Cannon Research Institute

Please refer to this study by its ClinicalTrials.gov identifier: NCT00550199

Contacts

Locations


United States, Tennessee
	Tennessee Oncology, PLLC	Recruiting
	Nashville, Tennessee, United States, 37023

Sponsors and Collaborators

Sarah Cannon Research Institute

SCRI Oncology Research Consortium

Novartis

Investigators


Study Chair:	Howard Burris, M.D.	SCRI Oncology Research Consortium